Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Intravesical chemotherapy

11 evidence topics · 9 sources

Guideline description: intravesical chemotherapy and chemotherapy combinations

“Valrubicin, an anthracycline topoisomerase inhibitor that interferes with deoxyribonucleic acid (DNA) synthesis and metabolism by inhibiting the activity of DNA topoisomerase II, leading to cell cycle arrest in the G2 phase, was approved by the FDA in 1998, but its use has been limited due to the availability of more effective options” (opens the source at this quote in a new tab)

“have been assessed in a small series of BCG-recurrent NMIBC patients usually not fulfilling the definition of BCG-unresponsive, with inconsistent results.” (opens the source at this quote in a new tab)

“sequential intravesical administration of gemcitabine and docetaxel is an emerging treatment option in patients failing BCG.” (opens the source at this quote in a new tab)

“In a retrospective series of 102 patients with BCG-unresponsive NMIBC, with or without CIS, 6-, 12-, and 24-month HG RFS was 78%, 65% and 49%, respectively.” (opens the source at this quote in a new tab)

“Fifty-seven percent of patients experienced mild/moderate adverse effects, the most common being represented by urinary frequency/urgency (41%) and dysuria (21%) and leading to treatment delay in only 7% of cases” (opens the source at this quote in a new tab)

“Notably, published data on this combination are currently predominantly retrospective, with only one small prospective series reported in Table 7.4” (opens the source at this quote in a new tab)

Gemcitabine alone compared with sequential gemcitabine and docetaxel: regimens and outcomes

“Patients received 2 g of gemcitabine in 100 mL of saline, instilled into the bladder via a catheter for a minimum of 60 minutes once weekly for 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients received 1 g of gemcitabine in 50 mL of saline, instilled via catheter for 60 to 90 minutes. The bladder was then drained, and 37.5 mg of docetaxel in 50 mL of saline was instilled via a catheter for 60 to 120 minutes. This treatment sequence was administered weekly for 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Median HGRFS was similar between groups (gemcitabine: 22.6 months; Gem/Doce: 19.5 months [P=.25]). Among patients with BCG-unresponsive carcinoma in situ (n=49), median HGRFS was comparable (gemcitabine: 12.2 months; Gem/Doce: 7.6 months [P=.12]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Low-grade adverse events were common (gemcitabine: 63%; Gem/Doce: 55% [P=.19]), but grade ≥3 adverse events were rare (2.3% vs 2.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Sequential Gem/Doce also poses logistical barriers, including extended chair time, sequential instillation, staffing demands, and reimbursement issues, which may limit its adoption, especially in community settings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote